Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer

Journal of the National Cancer Institute

Volumn 104, Issue 17, 2012, Pages 1306-1319

  Marshall, Jean Claude A ^a,g   Collins, Joshua W ^a   Nakayama, Joji ^a   Horak, Christine E ^a,f   Liewehr, David J ^b   Steinberg, Seth M ^b   Albaugh, Mary ^c   Vidal Vanaclocha, Fernando ^d   Palmieri, Diane ^a   Barbier, Maryse ^e   Murone, Maximilien ^e   Steeg, Patricia S ^a  

^a Women's Cancers Section   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSIDAD SAN PABLO CEU   (Spain)

^e DEBIOPHARM SA   (Switzerland)

^f BRISTOL MYERS SQUIBB   (United States)

^g Center for Translational Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; DEBIO 0719; KI 67 ANTIGEN; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38; RECEPTOR BLOCKING AGENT; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LIVER METASTASIS; LUNG METASTASIS; METASTASIS DORMANCY; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR VOLUME; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; EIF-2 KINASE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; ISOXAZOLES; KI-67 ANTIGEN; LIVER NEOPLASMS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROPIONATES; RANDOM ALLOCATION; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, SMALL INTERFERING;

EID: 84866061054     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs319     Document Type: Article

References (98)

1. Yoshida B, Sokoloff M, Welch D, Rinker-Schaeffer C. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst. 2000;92(21):1717-1730.
2. Steeg P. Metastasis suppressors alter the signal transduction of cancer cells. Nat Cancer Rev. 2003;3(1):55-63. (Pubitemid 37328887)
3. Rinker-Schaeffer CW, O'Keefe J P, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res. 2006;12(13):3882-3889. (Pubitemid 44078070)
4. Kauffman E, Robinson V, Stadler W, Sokoloff M, Rinker-Schaeffer C. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol. 2003;169(3):1122-1133. (Pubitemid 36188186)
5. Smith S, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer. 2009;9(4):253-264.
6. Stafford LJ, Vaidya KS, Welch DR. Metastasis suppressors genes in cancer. Int J Biochem Cell Biol. 2008;40(5):874-891.
7. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988;80(3):200-204.
8. Rosengard AM, Krutzsch HC, Shearn A, et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature. 1989;342(6246):177-180.
9. Leone A, Flatow U, King CR, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell. 1991;65(1):25-35. (Pubitemid 121001210)
10. Subramanian C, Cotter M, Robertson E. Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med. 2001;7(3):350-355. (Pubitemid 32224352)
11. Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene. 1993;8(9):2325-2333. (Pubitemid 23252360)
12. Bhujwalla Z, Aboagye E, Gillies R, Chacko V, Mendola C, Backer J. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med. 1999;41(5):897-903. (Pubitemid 29211131)
13. Russell R, Geisinger K, Mehta R, White W, Shelton B, Kute T. nm23-rela-tionship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients. Cancer. 1997;79(6):1158-1165. (Pubitemid 27118213)
14. Fukuda M, Ishii A, Yasutomo Y, et al. Decreased expression of nucleoside diphosphate kinase alpha isoform, an nm23-H2 gene homolog, is associated with metastatic potential of rat mammary-adenocarcinoma cells. Int J Cancer. 1996;65(4):531-537. (Pubitemid 26083261)
15. Baba H, Urano T, Okada K, et al. Tw o isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res. 1995;55(9):1977-1981.
16. Miele ME, Rosa ADL, Lee JH, et al. Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (Nm23). Clin Exp Metastasis. 1997;15(3):259-265. (Pubitemid 27240356)
17. Parhar RS, Shi Y, Zou M, Farid NR, Ernst P, Al-Sedairy S. Effects of cytokine-mediated modulation of nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Int J Cancer. 1995;60(2):204-210.
18. Tagashira H, Hamazaki K, Tanaka N, Gao C, Namba M. Reduced meta-static potential and c-myc overexpression of colon adenocarcinoma cells (Colon 26 line) transfected with nm23-R2/rat nucleoside diphosphate kinase alpha isoform. Int J Mol Med. 1998;2(1):65-68.
19. Miyazaki H, Fukuda M, Ishijima Y, et al. Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture. Clin Cancer Res. 1999;5(12):4301-4307. (Pubitemid 30013819)
20. Suzuki E, Ota T, Tsukuda K, et al. nm23-H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation. Int J Cancer. 2004;108(2):207-211. (Pubitemid 37541772)
21. Che G, Chen J, Liu L, et al. Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma. 2006;53(6):530-537. (Pubitemid 46137770)
22. D'Angelo A, Garzia L, André A, et al. Prune cAMP phosphodies-terase binds nm23-H1 and promotes cancer metastasis. Cancer Cell. 2004;5(2):137-149. (Pubitemid 38283800)
23. Boissan M, Wendum D, Arnaud-Dabernat S, et al. Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(11):836-845. (Pubitemid 40909126)
24. Titus B, Frierson HF Jr, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 2005;65(16):7320-7327. (Pubitemid 41161264)
25. Sur S, Pagliarini T, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A. 2009;106(9):3064-3969.
26. Horak CE, Lee JH, Elkahloun AG, et al. Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res. 2007;67(15):7238-7246. (Pubitemid 47206552)
27. Horak CE, Mendoza A, Vega-Valle E, et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res. 2007;67(24):11751-11759.
28. Murph MM, Nguyen GH, Radhakrishna H, Mills GB. Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta. 2008;1781(9):547-557.
29. Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol. 2000;58(6):1188-1196.
30. Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem. 2002;131(6):767-771. (Pubitemid 34717578)
31. Luquain C, Sciorra VA, Morris AJ. Lysophosphatidic acid signaling: how a small lipid does big things. Trends Biochem Sci. 2003;28(7):377-383. (Pubitemid 36851619)
32. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays. 2004;26(8):870-881. (Pubitemid 39128101)
33. Mills G, Moolenaar W. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3(8):582-591. (Pubitemid 37328830)
34. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem. 2004;279(20):20555-20558. (Pubitemid 38656446)
35. Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277(4):48737-48744. (Pubitemid 35470839)
36. Liu S, Umezu-Goto M, Murph M, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009;15(6):539-550.
37. Chen M, Towers LN, O'Connor KL. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol, Cell Physiol. 2007;292(5): C1927-C1933. (Pubitemid 47080564)
38. Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004;279(1):17634-17639. (Pubitemid 38560528)
39. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA. 2006;103(25):9643-9648. (Pubitemid 43955878)
40. Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 2003;63(7):1706-1711. (Pubitemid 36373664)
41. Komachi M, Tomura H, Malchinkhuu E, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 2009;30(3):457-465.
42. Waters C, Saatian B, Moughal N, et al. Integrin signalling regulates the nuclear localization and function of the lysophosphatidic acid receptor-1 (LPA1) in mammalian cells. Biochem J. 2006;398(1):55-62. (Pubitemid 44231301)
43. Yu S, Murph M, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and agressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008;20(22):1630-1642.
44. Zhang H, Xu X, Gajewiak J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009;69(13):5441- 5449.
45. Peyruchaud O. Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer. Anticancer Agents Med Chem. 2009;9(4):381-391.
46. Kano K, Arima N, Ohgami M, Aoki J. LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-2131.
47. Ohta H, Sato K, Murata N, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003;64(4):994-1005. (Pubitemid 37153068)
48. Prestwich G, Gajewiak J, Zhang H, Xu X, Yang G, Serban M. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta. 2008;1781(9):588-594.
49. Mukai M, Imamura F, Ayaki M, et al. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). Int J Cancer. 1999;81(6):918-922. (Pubitemid 29249977)
50. Palmieri D, Halverson D, Ouatas T, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst. 2005;97(9):632-642. (Pubitemid 40812627)
51. Fitzgerald D, Palmieri D, Hua E, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008;25(7):799-810.
52. Ta o K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008;8:228.
53. Aguirre-Ghiso J, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003;63(7):1684-1695. (Pubitemid 36373662)
54. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 2004;64(20):7336-7345. (Pubitemid 39372072)
55. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res. 2007;5(2):195-201. (Pubitemid 46424000)
56. Li T, Alemayehu M, Aziziyeh A, et al. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res. 2009;7(7):1064-1077.
57. Park S, Schinkmann K, Avraham S. RAFTK/Pyk2 mediates LPA-induced PC12 cell migration. Cell Signal. 2006;18(7):1063-1071.
58. Sawada K, Morishige K, Tahara M, et al. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol. 2002;87(3):252-259. (Pubitemid 36034644)
59. Bian D, Mahanivong C, Yu J, et al. The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene. 2006;25(15):2234-2244.
60. Bian D, Su S, Mahanivong C, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res. 2004;64(12):4209-4217. (Pubitemid 38802425)
61. Jung I, Lee J, Lee K, et al. Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells. Eur J Biochem. 2004;271(8):1557-1565. (Pubitemid 38553561)
62. Malchinkhuu E, Sato K, Horiuchi Y, et al. Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophos-phatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene. 2005;24(44):6676-6688. (Pubitemid 41486798)
63. Keshet Y, Seger R. The MAP Kinase Signaling Cascades: A System of Hundreds of Components Regulates a Diverse Array of Physiological Functions. 2nd ed. New York, NY: Springer; 2010.
64. Adler H, Steinbrink K. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle. 2008;7(2):169-170.
65. Pillai M, Sapna S, Shivakumar K. p38 MAPK regulates G1-S transition in hypoxic cardiac fibroblasts. Int J Biochem Cell Biol. 2011;43(6):919-927.
66. Inokuchi M, Uetake H, Shirota Y, Yamada H, Tajima M, Sugihara K. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol. 2004;53(5):391-396. (Pubitemid 38553660)
67. Taylor J, Hickson J, Lotan T, Yamada DS, Rinker-Schaeffer C. Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer Metastasis Rev. 2008;27(1):67-73.
68. Swaney J, Chapman C, Correa L, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010;160(7):1699-1713.
69. Steeg P, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol. 2008;5(4):206-219. (Pubitemid 351493680)
70. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895-904. (Pubitemid 44175140)
71. Stoecklein N, Klein C. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126(3):589-598.
72. Goss P, Chambers A. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer. 2010;10(12):871-877.
73. Aguirre-Ghiso J. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-846. (Pubitemid 350006258)
74. Noltenius C, Noltenius H. Dormant tumor cells in liver and brain. An autopsy study on metastasizing tumors. Pathol Res Pract. 1985;179(4-5):504-511. (Pubitemid 15103256)
75. Goodison S, Kawai K, Hihara J, et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmet-astatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res. 2003;9(10 Pt 1):3808-3814. (Pubitemid 37169252)
76. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998;101(5):1055-1063. (Pubitemid 28125284)
77. McAllister S, Gifford A, Greiner A, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994-1005. (Pubitemid 351787747)
78. Willis L, Alarcón T, Elia G, et al. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res. 2010;70(11):4310- 4317.
79. Uhr J, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA. 2011;108(30):12396-12400.
80. Naumov G, Townson J, MacDonald I, et al. Ineffectiveness of doxo-rubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003;82(3):199-206. (Pubitemid 37521976)
81. Shin J-S, Woo S, Lee H-C, et al. Low doses of ionizing radiation suppress doxorubicin-induced senescence-like phenotypes by activation of ERK1/2 and suppression of p38 kinase in MCF7 human breast cancer cells. Int J Oncol. 2010;36(6):1445-1452.
82. Bertelsen M, Sanfridson A. TAB1 modulates IL-1alpha mediated cytokine secretion but is dispensable for TAK1 activation. Cell Signal. 2007;19(3):646-657. (Pubitemid 46127538)
83. Ogata S, Kubota Y, Yamashiro T, et al. Signaling pathways regulating IL-1alpha-induced COX-2 expression. J Dent Res. 2007;86(2):186-191.
84. Santos L, Fan H, Hall P, et al. Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum. 2011;63(4):960-970.
85. Kumar V, Behera R, Lohite K, Karnik S, Kundu G. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 2010;70(24):10381-10391.
86. Thömmes K, Hoppe J, Vetter H, Sachinidis A. The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signaling pathways. Exp Cell Res. 1996;226(1):59-66. (Pubitemid 26238927)
87. Odemis V, Boosmann K, Heinen A, Küry P, Engele J. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci. 2010;123(Pt 7):1081-1088.
88. Bigelow R, Williams B, Carroll J, Daves L, Cardelli J. TIMP-1 overex-pression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat. 2009;117(1):31-44.
89. Li Y, Li Y, Qian Z, Ryu B, Kim S. Suppression of vacular endothelial growth factor (VEGF) induced angiogenic responses by fucodiphloroethol G. Process Biochem. 2011;46(5):1095-1103.
90. Peters I, Tossidou I, Achenbach J, et al. IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol. 2006;17(6):1644-1656. (Pubitemid 43794667)
91. Hua F, Henstock P, Tang B. ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release. Int Immunopharmacol. 2010;10(7):730-737.
92. Fan S, Meng Q, Laterra J, Rosen E. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem. 2009;284(12):7561-7577.
93. Kim Y, Min K, Jeong D, Jang J, Kim H, Kim E. Effects of fibroblast growth factor-2 on the expression and regulation of chemokines in human dental pulp cells. J Endod. 2010;36(11):1824-1830.
94. Klosowska K, Volin M, Huynh N, Chong K, Halloran M, Woods J. Fractalkine functions as a chemoattractant for osteoarthritis synovial fibro-blasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. Clin Exp Immunol. 2009;156(2):312-319.
95. Campbell M, Collery R, McEvoy A, Gardiner T, Stitt A, Brankin B. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function. Curr Eye Res. 2006;31(12):1033-1045. (Pubitemid 46005570)
96. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg D. Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain micro-vascular endothelial cells. Stroke. 2003;10(10):2483-2488. (Pubitemid 37221969)
97. Yamochi T, Yamochi T, Aytac U, et al. Regulation of p38 phospho-rylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res. 2005;65(5):1973-1983. (Pubitemid 40478627)
98. Griend D, Kocherginsky M, Hickson J, Stadler W, Lin A, Rinker-Schaeffer C. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 2005;65(23):10984-10991. (Pubitemid 41713368)